The Memo: Vascudyne Engineering Regenerative Tissue for Cardiovascular Repair
Under the direction of CEO Zeeshan Syedain, PhD, Vascudyne is developing off-the-shelf, regenerative tissue implants designed to integrate with the patient’s body and remodel into living tissue. The St. Paul, Minnesota-based company is advancing engineered blood vessels and heart valves, with its lead clinical program focused on coronary artery bypass grafting (CABG) and additional work targeting congenital heart defects. Vascudyne’s approach centers on a human cell-derived biological matrix rather than synthetic material, with the goal of giving surgeons a readily available biological implant that can become populated by the patient’s own cells over time. Origin Story Vascudyne’s technology originated in Professor Robert Tranquillo’s lab at the University of Minnesota, where Dr. Syedain earned his PhD. As a co-inventor of the company’s core technology, his research centered on a fundamental question: could a bioengineered blood vessel or heart valve be grown in the lab and ultimately ...